title: Felodipine in the treatment of patients with severe hypertension and impaired renal function.
abstract: Twenty-three patients with severe hypertension and impaired renal function were included in an open study of the efficacy and tolerance of felodipine treatment over 6 months. All patients were previously treated with a diuretic, a beta blocker, and a vasodilator, and eight of them also received an ACE inhibitor. At the start of felodipine treatment the previously used vasodilator was withdrawn. In nine patients the concomitant antihypertensive treatment was reduced during the study. The glomerular filtration rate (GFR), as 51Cr EDTA clearance, was determined before and at the end of the study. The blood pressure (BP) and heart rate (HR) were recorded at all clinical visits in the morning 12 hours after the evening dose of felodipine and 2 hours after the morning dose. Plasma concentrations of felodipine were measured at every visit before the morning dose and 2 hours after dose. The BP was reduced after felodipine was substituted for the previously used vasodilator. A significant additional anti-hypertensive effect was recorded 2 hours after the dose and amounted to -37 +/- 22/-15 +/- 12 mmHg (p = 0.0001/p = 0.0002) at 6 months. The effect measured 12 hours after the dose was less pronounced and was -11 +/- 28/-6 +/- 10 mmHg (p = 0.15/p = 0.03). Mean GFR was unchanged during the study, 38 +/- 19 versus 38 +/- 19 ml/min (n = 16). There was a sixfold interindividual variation in the trough plasma concentrations at steady state at the same drug dosage. Higher plasma concentrations seemed to be required to achieve the same antihypertensive effects as in patients with less severe hypertension and normal renal function.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Nephrology, Linköping University Hospital, Sweden.
authors.forename: R
authors.initials: R
authors.lastname: Larsson
authors.forename: M K
authors.initials: MK
authors.lastname: Lindsjö
authors.forename: B
authors.initials: B
authors.lastname: Danielsson
authors.forename: U
authors.initials: U
authors.lastname: Bengtsson
authors.forename: J H
authors.initials: JH
authors.lastname: Hardlund
authors.forename: P A
authors.initials: PA
authors.lastname: Sjöström
authors.forename: D
authors.initials: D
authors.lastname: Elmfeldt
authors.forename: L
authors.initials: L
authors.lastname: Moberg
mesh_terms: D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D015736:Felodipine / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D006977:Hypertension, Renal / Q000188:drug therapy; D007674:Kidney Diseases / Q000150:complications / Q000503:physiopathology*; D007677:Kidney Function Tests; D008297:Male; D008875:Middle Aged; D012720:Severity of Illness Index
chemical_list: D015736:Felodipine